Lung adenocarcinoma with lepidic growth
DOI:
https://doi.org/10.32818/reccmi.a5n3a5Keywords:
adenocarcinoma, lung cancer, lepidic, tyrosine kinase.Abstract
Lung adenocarcinoma is a type of cancer characterized by the presence of multiple histological subtypes with a wide variety of clinical and radiological manifestations. Some of them show a remarkable lepidic growth on the alveolar surface without invading the underlying structures. We report a 60-year-old patient with a clinical onset suitable with multilobar pneumonia. After hospitalization, the diagnostic tests concluded the presence of a lepidic pattern lung adenocarcinoma. The patient received oncological treatment with tyrosine kinase inhibitor drugs based on the tumor pharmacogenetics.Downloads
Metrics
References
Barta JA, Powell CA, Wisnivesky JP. Global Epidemiology of Lung Cancer. Ann Glob Health. 2019; 85(1): 8, 1-16. doi: https://doi.org/10.5334/aogh.2419.
Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB et al; WHO Panel. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015; 10(9): 1243-1260. doi: https://doi.org/10.1097/JTO.0000000000000630.
Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I et al; Pneumonia Guidelines Committee of the BTS Standards of Care Committee. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009; 64 Suppl 3: iii1-55. doi: https://doi.org/10.1136/thx.2009.121434.
Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF et al. The Global Burden of Cancer 2013. JAMA Oncol. 2015; 1(4): 505-27. doi: https://doi.org/10.1001/jamaoncol.2015.0735.
Leiro-Fernández V, Mouronte-Roibás C, Ramos-Hernández C, Botana-Rial M, González-Piñeiro A, García-Rodríguez E et al. Changes in clinical presentation and staging of lung cancer over two decades. Arch Bronconeumol. 2014; 50(10): 417-21. doi: https://doi.org/10.1016/j.arbres.2014.03.003.
Chute CG, Greenberg ER, Baron J, Korson R, Baker J, Yates J. Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont. Cancer. 1985; 56(8): 2107-11. doi: https://doi.org/10.1002/1097-0142(19851015)56:8%3C2107::AID-CNCR2820560837%3E3.0.CO;2-T.
Reck M, Rabe KF. Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(9): 849-861. doi: https://doi.org/10.1056/NEJMra1703413.
Villar Álvarez F, Muguruza Trueba I, Belda Sanchis J, Molins López-Rodó L, Rodríguez Suárez PM, Sánchez de Cos Escuín J et al. Executive summary of the SEPAR recommendations for the diagnosis and treatment of non-small cell lung cancer. Arch Bronconeumol. 2016; 52(7):378-88. doi: https://doi.org/10.1016/j.arbres.2016.02.016.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Daniel Etxeberria-Lekuona, Amaia Atenea Iridoy-Zulet
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
